Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy
-
- Yokokawa Tetsuro
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan Department of Pulmonary Hypertension, Fukushima Medical University, Japan
-
- Yoshihisa Akiomi
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan Department of Advanced Cardiac Therapeutics, Fukushima Medical University, Japan
-
- Misaka Tomofumi
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan Department of Advanced Cardiac Therapeutics, Fukushima Medical University, Japan
-
- Sato Takamasa
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan
-
- Kaneshiro Takashi
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan
-
- Oikawa Masayoshi
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan
-
- Kobayashi Atsushi
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan
-
- Yamaki Takayoshi
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan
-
- Kunii Hiroyuki
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan
-
- Takeishi Yasuchika
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan
Search this article
Abstract
<p>Objective It has been reported that anti-mitochondrial antibodies (AMAs) recognize mitochondrial antigens and are associated with some diseases involving multiple organs, such as primary biliary cholangitis, Sjögren syndrome, Hashimoto's thyroiditis, systemic sclerosis, interstitial pneumoniae, dilated cardiomyopathy, and tubulointerstitial nephritis. In the current study, we examined the prevalence of AMAs in patients with dilated cardiomyopathy (DCM) and their clinical characteristics. </p><p>Methods We enrolled 270 patients with DCM. We measured serum AMAs and analyzed the associated factors. Out of the 270 patients, positive AMAs were detected in 3 patients (1.1%; mean age, 68 years old; 2 men). These three patients had a significantly higher prevalence of primary biliary cholangitis and myopathy and levels of alanine alkaline phosphatase than those who were negative for said antibodies. There were no significant differences in the levels of B-type natriuretic peptide, aspartate transaminase, and left ventricular ejection fraction between these groups of patients. During the follow-up period, two of the three patients died due to respiratory failure. The other patient survived but experienced type II respiratory failure. </p><p>Conclusion The prevalence of AMAs in 270 DCM patients was only 1.1%, and these patients suffered from respiratory failure. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 60 (2), 201-208, 2021-01-15
The Japanese Society of Internal Medicine
